Analysts’ Opinions Are Mixed on These Financial Stocks: Bank Of Montreal (BMO), JPMorgan Chase (JPM) and CME Group (CME)
Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Bank Of Montreal (BMO – Research Report), JPMorgan Chase (JPM – Research Report) and CME Group (CME – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bank Of Montreal (BMO)
Canaccord Genuity analyst Matthew Lee maintained a Buy rating on Bank Of Montreal today and set a price target of C$218.00. The company’s shares closed last Tuesday at $142.30.
According to TipRanks.com, Lee is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bank Of Montreal with a $146.11 average price target, a 2.9% upside from current levels. In a report issued on February 13, Raymond James also upgraded the stock to Buy with a C$214.00 price target.
See today’s best-performing stocks on TipRanks >>
JPMorgan Chase (JPM)
Truist Financial analyst John McDonald CFA maintained a Hold rating on JPMorgan Chase today and set a price target of $330.00. The company’s shares closed last Tuesday at $297.30.
According to TipRanks.com, CFA is a 4-star analyst with an average return of
Currently, the analyst consensus on JPMorgan Chase is a Moderate Buy with an average price target of $346.82, implying a 16.8% upside from current levels. In a report issued on February 17, Morgan Stanley also maintained a Hold rating on the stock with a $365.00 price target.
CME Group (CME)
In a report released yesterday, William Katz from TD Cowen maintained a Buy rating on CME Group, with a price target of $328.00. The company’s shares closed last Tuesday at $319.03.
According to TipRanks.com, Katz is a 5-star analyst with an average return of
CME Group has an analyst consensus of Hold, with a price target consensus of $300.38.
